

## "Radiologically isolated syndrome"

Teaching Course 4  
October 27th 2019

Aksel Siva, M.D.  
MS Clinic & Department Of Neurology  
Istanbul University Cerrahpaşa School of Medicine  
akselsiva@gmail.com



## Disclosure

- Received honoraria for educational presentations and consultation fees from Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Biogen Idec/Gen Pharma of Turkey, Bayer, Merck Serono and Teva; received travel and registration coverage for attending several national or international congresses or symposia, from Genzyme and F. Hoffmann-La Roche
- Received research grants from The Istanbul University Research Foundation & The Scientific and Technological Research Council Of Turkey

## "Radiologically Isolated Syndrome"

### Outline

- Diagnosing diseases in the preclinical stage!
- Asymptomatic MS
- Definition & Background & Overview
- "Evolution from postmortem to premortem recognition"
- "Radiologically isolated syndrome (RIS)"
- Current concepts and clinical implications
- Recent data and what to expect?

## Diagnosing diseases in their preclinical stage! Multiple Sclerosis

- The pathophysiological process of MS is known to begin many years before the diagnosis of of the clinical disease...
- In most patients presenting with the first clinical episode of MS there are already several silent/asymptomatic old MRI lesions consistent with MS (and in some already atrophy and T1 black holes) indicating that the disease had already started some time ago...
- The presence of OCBs and elevated titers of IgG in the CSF, as well as detecting some specific biomarkers (before or at the time of Dx) are further evidence of ongoing early CNS neuro-inflammation and neuro-degeneration...

## "Asymptomatic MS"

### Definition

- "Asymptomatic MS / Subclinical-MS"
- When clinically silent disease is diagnosed by chance, either at autopsy or by MRI (then diagnosed as "RIS") or biologically - by CSF studies & other findings suggestive of an underlying probable demyelinating-inflammatory disorder! [in individuals with no MS related symptoms & signs]
- Radiologically isolated syndrome (RIS)
- is a form of "Asymptomatic MS"
- But not all "Asymptomatic MS" cases are "RIS"

## Asymptomatic MS "Radiologically isolated syndrome"

### Clinical problems!

- The increasing use of MRI in various neurological problems or for other causes may reveal cases of "Asymptomatic Multiple Sclerosis - RIS" whose long term clinical behaviour is unknown but also some incidental nonspecific white matter abnormalities may be mistaken to be suggestive of MS and may cause some confusion for the unexperienced physician!


## Asymptomatic MS / RIS

Further questions...

Prior to the clinical diagnosis of MS...

- Does every MS patient has a pre-clinical "silent" phase?
- How early is the CNS involvement histologically?
- How widespread is it?
- How severe is it?
- Is there a time span for the active duration of the disease?
- How, when, why and in whom the subcl/clinical disease stops?

## Asymptomatic MS - postmortem studies



## Asymptomatic MS - postmortem studies

Unsuspected Multiple Sclerosis

REPORT OF CASES

CASE 1.—A 39-year-old man was admitted to the hospital for palliative care for uremia. He had juvenile-onset diabetes.

(Fig 1). Microscopic examination con-

As the previous the majority of and were relatively small...

Is it a very mild form of the disease?

Is it a self-limited process?

Do number, severity & location matters?

- Is inflammation an early isolated event in asymptomatic MS? Is it mild?
- Does the MS lesion/s are limited in number and remain self limited in asymptomatic cases? No tissue destruction - no degeneration???

## Asymptomatic MS - postmortem studies

A clinical patho-anatomical study of clinically silent multiple sclerosis

It may be concluded that there are clinically "silent" areas in the central nervous system.

Is it simply the location "PV-silent areas" or the severity of inflammation and/or other pathological features that governs clinical behaviour?

The rate of finding unexpected MS lesions in neuropathological examinations 0,08% - 0,2%

## Asymptomatic MS - postmortem studies

Postmortem rate (prevalence) of "clinically silent" MS

- Basel Institute of Pathological Anatomy\*
- 66 / 15,644 autopsies cases of anatomically demonstrated MS
  - (postmortem MS prevalence rate of 0.4 %)
  - 54 had a confirmed clinical Dx of MS or OND
  - 12 had "incidental" autopsy findings - clinically silent MS
  - rate of "clinically silent" disease: 18% of a postmortem MS cohort
- Danish MS Register of all autopsied cases of MS (1965-86)\*\*
- clinically silent MS mean frequency: 0.08%
  - 40 persons / year die with clinically silent MS
  - corresponding to 25% of deceased persons with an in vivo dx of MS

\*Georgi, 1961; \*\*Engell, 1989

## Asymptomatic (Subclinical) MS

In asymptomatic family members of MS patients (and incidentally in anybody[?])

- MRI: Lesions consistent with MS\*
- CSF: OCB (+)\*\*
- EP: abnormal\*\*\*



In non-MS autopsies, sporadic cases with incidental lesions consistent with MS are found

For every diagnosed 4 - 5 "clinical MS patient" probably there is one other asymptomatic - undiagnosed individual with subclinical disease!

\*Uidehaag et al. JNNP 1989; Lynch et al. Neurology 1990; Tienari et al. JNNP 1992; Sadovnick, et al. Ann Neurol. 1993; Constantinescu et al. Mult Scler 1995; Fulton et al. Mult Scler 1999; \*\*Xian-hao & McFarlin DE. Neurology 1984; \*\*\*Nawer et al. Ann Neurol 1985

## Asymptomatic MS and CSF findings

**Oligoclonal bands in CSF: Twins with MS**  
Xian-hao Xu, MD, and Dirk H. McFarlin, MD

**Cerebrospinal fluid findings in healthy siblings of multiple sclerosis patients**  
From Duquette, MD, and Charest, L, MD

**Incidence of CSF abnormalities in siblings of multiple sclerosis patients and unrelated controls**  
Haghighi S, Anderson A, Oksa A, Ransmayr G, Christenson R, et al.

**Cerebrospinal fluid markers in MS patients and their healthy siblings**  
Haghighi S, Anderson A, Oksa A, Ransmayr G, Christenson R, et al.

\*Xian-hao & McFarlin DE. Neurology 1984; \*Duquette P & Charest L. Neurology, 1986  
\*\* Haghighi S, et al. J Neurol 2000; \*\*\* Haghighi S, et al. Acta Neurol Scand, 2004

## Asymptomatic MS and CSF findings

**MS immunopathic trait**  
Asymptomatic first-degree relatives of MS patients may have oligoclonal bands (OCB) in the CSF \*\*/\*\*/\*\*

19% of (vs 4% of normal CSF) CSF-OCBs

No evidence of significant neuronal-tissue damage in asymptomatic individuals with probable biologic findings suggestive of MS (indicating damage)\*\*\*

vs normal CSF (indicating damage)\*\*\*


the MS group (indicating damage)\*\*\*

trait siblings (indicating damage)\*\*\*

\* Xian-hao & McFarlin DE. Neurology 1984; \* Duquette P & Charest L. Neurology, 1986  
\*\* Haghighi S, et al. J Neurol 2000; \*\*\* Haghighi S, et al. Acta Neurol Scand, 2004  
NFL: neurofilament light protein; GFAP: glial fibrillary acidic protein

## "Asymptomatic Multiple Sclerosis"

Asymptomatic lesions in patients with CIS/MS in most patients presenting with the first clinical episode of MS there will be several silent or asymptomatic «old» MRI lesions that are consistent with MS



23 yrs old F diagnostic MRI at onset with "ON"      27 yrs old M - diagnostic MRI at onset with "gait difficulty"

## Asymptomatic MS / Subclinical-MS

Focal brain abnormalities indistinguishable from those of MS occur in asymptomatic first-degree relatives of MS patients

A lesional MRI similar to that of MS

No evidence of significant neuronal-tissue damage in asymptomatic individuals with radiologic findings suggestive of MS

WM lesions of NC in NAWM associated with widespread tissue damage commonly found in MS patients

indicating the associated with widespread tissue damage commonly found in MS patients

DeStefano et al. Ann Neurol 2006

## Asymptomatic MS Radiologically Isolated Syndrome

**Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile**

**Incidental MRI anomalies suggestive of multiple sclerosis**  
The radiologically isolated syndrome

**Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease**

Lebrun et al JNNP, 2008  
Okada et al Neurology, 2009  
Siva et al Multiple Sclerosis, 2009

## The Radiologically Isolated Syndrome Consortium (RISC) Core Group - 2009

**Aksel Siva**  
Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey

**Darin Okuda**  
University of Texas Southwestern Medical Center, Dallas, Texas, US

**Orhun Kantarci**  
Mayo Clinic and Foundation, Rochester, USA

**Christine Lebrun**  
Club Francophone de la Sclerose en Plaques, Hôpital Pasteur, Nice Cedex, France

**Daniel Pelletier**  
University of South California, California, USA

## Radiologically Isolated Syndrome - dx criteria\*

No clinical symptoms or signs suggestive MS

MRI done for another condition related to MS

An initial MRI fulfilled MRI criteria for RIS

MRI - CNS abnormalities not associated with any functional impairment

MRI anomalies in the CNS not better accounted for by another disease process

MRI anomalies not associated with any functional impairment

Okuda et al. Neurology, 2009

## "Radiologically Isolated Syndrome"

OPEN ACCESS Freely available online

PLOS ONE

### Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event


Darin T. Okuda<sup>1\*</sup>, Akshai Siva<sup>2</sup>, Oyvun Kantarci<sup>3</sup>, Mattiello Inglesse<sup>4</sup>, Ilana Katz<sup>5</sup>, Melih Tutuncu<sup>6</sup>, B. Mark Keegan<sup>7</sup>, Stacy Davidson<sup>8</sup>, Le H. Hsu<sup>9</sup>, Angela Vidal-Jordana<sup>2</sup>, Xavier Montalban<sup>2</sup>, Alex Rovina<sup>2</sup>, Mar Tintore<sup>2</sup>, Maria Pia Amato<sup>10</sup>, Bruno Brochet<sup>11</sup>, Jérôme de Seze<sup>10</sup>, David Brassat<sup>12</sup>, Maria Pia Sormani<sup>13\*</sup>, Daniel Pelletier<sup>13\*</sup>, Christine Lebrun<sup>14\*</sup>

Syndrome Consortium (RISC) and Club Francophone de la Sclérose en Plaques (CFCP)

<sup>1</sup> University of Illinois, Department of Neurology, Department of Neurology & Neuroimmunology, Chicago, Illinois, United States of America, <sup>2</sup> University of Navarra, Department of Neurology, Complutense University of Madrid, Madrid, Spain, <sup>3</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>4</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>5</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>6</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>7</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>8</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>9</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>10</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>11</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>12</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>13</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America, <sup>14</sup> University of Illinois, Department of Neurology, Department of Neurology, Chicago, Illinois, United States of America

- RIS cases: 451 (F: 78.5%)
- Mean age at Dx: 37.2 (±11.2)
- Familial MS: 9.9%
- CSF OCB+/IgG1: 64.7% (300 cases)

## Radiologically Isolated Syndrome converting to clinical disease\*



RIS - 5 and 10 years risk of developing an initial event consistent with "MS"

Results: At 10 yrs 51% of pwRIS had converted to clinical MS

Objective: To evaluate the 10-year risk for the development of the first symptomatic demyelinating event in a multinational cohort of RIS subjects

Age < 37 yr, positive CSF, spinal cord and PF lesions are risk factors for clinical evolution at 10yrs

\*Okuda et al. PLoS One, 2014 & Lebrun et al presented at ECTRIMS 2019

## "Radiologically Isolated Syndrome"

Novel imaging techniques as biomarkers of neuroinflammation and neuroregeneration and

The Radiologically Isolated Syndrome

...in fact currently most of what we know is based on the good old conventional MRI!

But some work is emerging with more sophisticated MRI techniques...

## RIS - are there/will be MRI predictors for conversion to clinical MS?

Macroscopic brain damage are similar in RIS and RRMS. However, the subtle tissue damage detected by MTR was milder in RIS than in RRMS / Lesional-MTR lower in RRMS than in RIS / NAWM-MTR and cortical-MTR similar in RIS and HC - lower in RRMS\*

Decreased brain NAA/Cr levels in a group of RIS subjects indicates that brain metabolic abnormalities suggestive of axonal damage can be significant even at this early stage. However, not all individuals with RIS have shown these abnormalities!\*

Not all RIS are early MS  
All RIS may not be the same!!!

\*De Stefano et al. PLoS ONE, 2011; \*\*Stromillo et al. Neurology 2013 & Okuda & Vernken. Neurology 2013

## RIS - how early the disease process starts? ...and what that does mean?


Cortical lesions (CLs) were found in 40% of asymptomatic subjects. CLs were not related to more pronounced cortical atrophy or

worse cognitive performance

Subjects with RIS with CLs had CSF (+) IgG OCBs & most had cervical spinal lesions on MRI - both risk factors for conversion. However, whether the occurrence of CLs in RIS can be interpreted as an indicator of possible clinical evolution to MS could not be established\*

Giorgio et al. Neurology 2011

## "Radiologically Isolated Syndrome" Evidence for early neurodegeneration!



**Conclusion:** Our data provide novel evidence of thalamic atrophy in RIS and are consistent with previous reports in early MS stages. Thalamic volume loss is present early in CNS demyelinating disease and should be further investigated as a metric associated with neurodegeneration

**Results:** Although additional normalized total gray and white matter volumes were not statistically different between patients with RIS and controls, normalized left  $0.0046 \pm 0.0005$  vs  $0.0049$

Azevedo et al, *Neurology* 2015

## "Radiologically Isolated Syndrome" Evidence for early neurodegeneration!



This study found minimal microstructural differences in the SC of RIS, despite most participants having visible lesions and no evidence of SC atrophy. MTR was lower in RIS, suggesting that inflammation and demyelination may be one of the only microstructural changes detectable in the very earliest stage of MS, which is in keeping with known pathologic mechanisms in MS

**Conclusion**  
The SC demonstrates minimal microstructural changes suggestive of demyelination and inflammation in RIS. These findings are in contrast to established MS and raise the possibility that the SC may play an important role in triggering clinical symptomatology in MS. Prospective follow-up of this cohort will provide additional insights into the role the SC plays in the complex sequence of events related to MS disease initiation and progression.

Some structural changes but no atrophy!

Alcaide-Leon et al, *Neurol Neuroimmunol Neuroinflamm*, 2018

## Radiologically Isolated Syndrome Pathologically Defined as Demyelinating Disease\*

- Three RIS patients where pathological examination confirmed CNS inflammatory demyelinating disease
- Presentations leading to imaging: intractable upper extremity pain, pituitary investigation for hormonal imbalance, and control volunteer for MRI study
- mean age at initial MRI & biopsy: 36 years (range 29-43) [2F]
- Brain MRI showed a large (tumefactive) gad+ lesion with additional non-enhancing white matter lesion/s in each
- Pathology confirmed inflammatory demyelinating disease indistinguishable from classic MS pathology in all three cases

\*Keegan, et al. *AAN* 2016 & *Neurology*, 2016 (Supplement)

## Early changes in MS\*

- expression profiling of subcortical NAWM of MS brain tissue and control WM using microarray technology revealed the upregulation of a significant number of genes
- the MS brain is mounting a global defense against oxidative stress in order to preserve cellular function, even in areas remote from active inflammatory and demyelinating lesions
- This involves up regulation of genes that reflect a higher energy metabolism as well as genes involved in endogenous neuroprotection, which may affect all neural cell types

\*Zeiss et al *Brain Pathol* 2009 & Schaeren Wiemers, 2011 *ECTRIMS*


## Are all PPMS are primary progressive? Does RIS may present clinically as PPMS?\*

Of the 453 subjects with RIS, 128 evolved to symptomatic MS during the follow-up (113 developed a first acute clinical event consistent with CIS/MS, 15 evolved to PPMS). PPMS prevalence (11.7%) and onset age ( $49.1 \pm 12.1$ ) in the RIS group were comparable to other PPMS populations

Subjects with RIS evolve to PPMS at the same frequency as expected from general MS populations in an age-dependent manner. Besides age, unequivocal presence of spinal cord lesions and being male predicted evolution to PPMS. Our findings further suggest that RIS is biologically part of the MS spectrum

\*Kantarci et al. *ANN NEUROL* 2016;79:288-294

## Radiologically isolated syndrome in children\*



38 children with RIS (16 cites/6 countries) mean f/up time:  $4.8 \pm 5.3$  yrs  
A first clinical event consistent with CNS demyelination occurred in 16/38 children (42%) in a median of 2.0 yrs  
Radiologic evolution developed in 23/38 children (61%)

The presence of OCB in CSF & spinal cord lesions on MRI were associated with an increased risk of a first clinical event

\*Makhani et al, *Neurol Neuroimmunol Neuroinflamm* 2017

## "Radiologically Isolated Syndrome" Is there early cognitive involvement?

However, it was also noteworthy that neither the individuals with RIS, nor their family members had noticed any signs of cognitive deficits or changes!\*

RIS patients have a similar cognitive profile to MS patients!\*\*  
Q: Are these individuals, likely to be MS patients with an undiagnosed "clinically isolated syndrome" who present with cognitive dysfunction?

\*Hakiki et al. Euro J Neurol, 2008; \*\*Lebrun et al, Multiple Sclerosis 2010; Amato et al, Neurology, 2011

## "RIS" and cognitive involvement! What to think of it?

- Are individuals with RIS, who are found to have a similar cognitive profile with MS patients are likely to be undiagnosed CIS patients?
- But it's also known that neither these individuals with RIS, nor their family members were aware of any sign of cognitive deficits or changes with any functional outcome!
- Is it possible that some clinical signs may remain subclinical unless explored with special technics and tools (similar to the demonstration of subclinical disease by imaging)?
- Therefore, such "sophisticated findings" may not always predict conversion to clinical disease and may correlate with a "subclinical disease state" that may remain as such for long periods or even a lifetime\*

\*Siva A. Asymptomatic MS. Clinical Neurol Neurosurg, 2014

## Cognitive involvement in MS! Is it the early steps into the clinical disease?

Q. Is preclinical cognitive performance affected long before MS Dx?

- In a Norwegian study correlating the cognitive performance of all men born in 1950-95 that underwent conscription examination at ages 18-19 to the Norwegian MS registry to identify those later developing MS, and randomly selected controls
  - Men developed cognitive problems before apparent clinical symptoms develop
  - Those developing MS later than controls
- An Argentine study correlating cognitive performance of individuals with RRMS and PPMS to their first clinical symptoms
- However, in a study comparing cognitive performance of individuals with RRMS and PPMS to their first clinical symptoms, a significant difference was observed...\*\*\*

Cognitive problems may be present in all MS phenotypes before apparent clinical symptoms develop

- RRMS may start years prior to clinical presentation and disease processes
- PPMS could start decades prior to first apparent clinically detectable progressive symptoms

\*Cortese et al. Ann Neurol, 2017; \*\*Sinay et al. MSJ, 2014; \*\*\* Gunnarsson et al. Europ Neurol 2015

## The MS prodrome - Does it exist?

More frequent use of health care (more hospital admissions / physician claims and prescriptions) in patients with MS than in controls in the 5 years before a first demyelinating event, according to health administrative data, suggests the existence of a measurable multiple sclerosis prodrome.

In two other studies MS patients reported higher rates of fatigue or depression in the years prior to the initial neurologic episode of their MS diagnosis compared with non-MS controls\*\*

These observations are indicative that people with MS are likely to have non MS-specific health related problems in the years before they develop clinical MS! Suggestive that an "MS prodrome" may exist at least for some MS patients

\*Winjand et al. Lancet Neurol, 2017; \*\*Berger et al. MSJ 2013 & Byatt et al. J Neuropsych Clin Neurosci 2011

## Prognostic biomarkers in radiologically isolated syndrome\*

CSF CHI3L1 levels did not influence conversion to CIS and MS in people with RIS. But, CSF NfL levels and OCB were independent predictors of clinical conversion in patients with radiologically isolated syndrome\*/\*\*

Serum NfL levels were higher in pre-symptomatic PwMS compared to matched controls both 6 years (med) & 1 year (med) before the first MS symptoms  
The clinical onset of MS was associated with a marked increase in sNfL levels from a median level of 25 pg/ml to 45.1 pg/ml \*\*\*

\*Thouvenot et al. MSJ 2018 & 2019; \*\*Matute-Bianch et al. Brain 2018; \*\*\* Bjoernevik et al. JAMA Neurology, 2019

## Radiologically Isolated Syndrome Should it be treated with DMD or not?\*

- Current evidence doesn't support early treatment in individuals with RIS\*
- However, RIS patients may be followed by MRI every 6 mo in the first year, and then yearly for the next 2 years and at year 5 or until they develop clinical symptoms suggestive of MS!
- Individuals with "RIS", who have high risk factors (spinal cord lesions, younger age and male gender\*\*) & continuous MRI activity may be considered for treatment trials at this stage!
- "Asymp MS/RIS" says something -probably important- and we should understand better & consider this concept/ phenotype, when evaluating and making treatment decisions for our MS pts!

\*DeStefano & Siva. MSJ 2013 & Granberg et al. MSJ 2013; \*\*Okuda et al. PLoS One, 2014

## Radiologically Isolated Syndromes

The "ARISE" study in which whether DMF delays the rate and onset of the first clinical event consistent with MS vs placebo in individuals with high risk RIS had started in 2016 in the US\*  
*\*Okuda et al*

The "TERIS" study in which whether teriflunomide delays the rate and onset of the first clinical event consistent with MS vs placebo in individuals with high risk RIS had started in 2018 in Europe\*\*  
*\*\*Lebrun et al*

\*DeStefano & Siva. MSJ 2013 & Granberg et al. MSJ 2013; \*\*Okuda et al. PLoS One, 2014

## Acknowledge - RISC & MS Study Groups

Istanbul University  
Cerrahpaşa School of Medicine

Melih Tütüncü  
Uğur Uygunoğlu  
Cengiz Yalçinkaya

Ayşe Altıntaş  
Sabahattin Saip  
AKsel Siva

Hacettepe University  
School of Medicine  
Pinar Acar  
Aslı Tuncer  
Rana Karabudak

Istanbul Technical  
University

Timucin Avsar  
İlknur Melis Durası  
Elif Everest  
Eda Tahir Turanlı

Acibadem University, Ist.  
O. Uğur Sezerman

Club Francophone de la  
Sclerose en Plaques,  
Hôpital Pasteur  
Nice Cedex, France  
Christine Lebrun

Mayo Clinic, Rochester, MN

Mark Keegan  
Orhun Kantarci  
Burcu Zeydan

University of Texas  
Southwestern Medical Center  
Dallas, Texas  
Darin Okuda

University of South California  
California, USA  
Christina Azevedo  
Daniel Pelletier

Yale University Sch of Medicine  
New Haven, CT;  
Naila Makhani

Mt. Sinai School of Medicine  
New York, NY  
Matilde Inglese